首页> 外文期刊>Nature >Complex landscapes of somatic rearrangement in human breast cancer genomes
【24h】

Complex landscapes of somatic rearrangement in human breast cancer genomes

机译:人类乳腺癌基因组中体细胞重排的复杂情况

获取原文
获取原文并翻译 | 示例
       

摘要

Multiple somatic rearrangements are often found in cancer genomes; however, the underlying processes of rearrangement and their contribution to cancer development are poorly characterized. Here we use a paired-end sequencing strategy to identify somatic rearrangements in breast cancer genomes. There are more rearrangements in some breast cancers than previously appreciated. Rearrangements are more frequent over gene footprints and most are intrachromosomal. Multiple rearrangement architectures are present, but tandem duplications are particularly common in some cancers, perhaps reflecting a specific defect in DNA maintenance. Short overlapping sequences at most rearrangement junctions indicate that these have been mediated by non-homologous end-joining DNA repair, although varying sequence patterns indicate that multiple processes of this type are operative. Several expressed in-frame fusion genes were identified but none was recurrent. The study provides a new perspective on cancer genomes, highlighting the diversity of somatic rearrangements and their potential contribution to cancer development.
机译:在癌症基因组中经常发现多种体细胞重排。然而,重排的潜在过程及其对癌症发展的贡献的特征很差。在这里,我们使用配对末端测序策略来识别乳腺癌基因组中的体细胞重排。在某些乳腺癌中发生的重排比以前更多。重排在基因足迹上更常见,并且大多数是染色体内的。存在多种重排结构,但是串联重复在某些癌症中尤为常见,可能反映了DNA维持的特定缺陷。在大多数重排连接处的短重叠序列表明,它们是由非同源末端连接DNA修复介导的,尽管不同的序列模式表明这种类型的多个过程是有效的。确定了几个表达的框内融合基因,但没有一个是复发性的。该研究为癌症基因组提供了新的视角,强调了体细胞重排的多样性及其对癌症发展的潜在贡献。

著录项

  • 来源
    《Nature》 |2009年第7276期|1005-1010|共6页
  • 作者单位

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Lancer Research, 237 Fulham Road, London SW3 6JB, UK;

    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 2040, 3000 CA,Rotterdam, ThQ Netherlands;

    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 2040, 3000 CA,Rotterdam, ThQ Netherlands;

    Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA;

    Department of Genetics, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway;

    Department of Genetics, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway;

    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 2040, 3000 CA,Rotterdam, ThQ Netherlands;

    Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Lancer Research, 237 Fulham Road, London SW3 6JB, UK;

    The Netherlands Cancer Institute, 121 Plesmanlaan, 1066 CX Amsterdam, The Netherlands;

    Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA;

    Department of Genetics, Norwegian Radium Hospital, Oslo University Hospital, Montebello, N-0310 Oslo, Norway Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Montebello, 0310 Oslo, Norway;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK;

    Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK Institute of Cancer Research, 5utton, Surrey SM2 5NG, UK;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:55:45

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号